Cancer

News

Zytiga generics looming as US court nixes J&J patent

Johnson & Johnson has lost another round in its patent defence for prostate cancer blockbuster Zytiga, raising the possibility that generics could launch in the coming days.

Views & Analysis

The Frauenkirche is a church in the Bavarian city of Munich that serves as the cathedral of the Archdiocese of Munich and Freising and seat of its Archbishop.

ESMO round-up: Big win for AstraZeneca in ovarian cancer, an...

Several drugmakers announced significant trial findings at this week’s European Society for Medical Oncology (ESMO) conference in Munich.

News

Chronic lymphocytic leukemia (CLL) is a type of cancer of the blood and bone marrow - the spongy tissue inside bones where blood cells are made.

AbbVie's CLL drug Venclyxto too expensive for NHS, says NICE

NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche's MabThera/Rituxan (rituximab), is not a cost-effective use of NHS resources as a treatment for

News

Innate Pharma gains rights to AZ's recently approved leukaem...

France’s Innate Pharma has gained rights to AstraZeneca's recently approved leukaemia drug Lumoxiti, in a deal that expands a collaboration that began more than three years ago.

News

Bayer plans filings for prostate cancer drug darolutamide

Bayer is planning regulatory filings of darolutamide in prostate cancer following phase III trial results showing it helped prevent the disease from spreading, in a niche where Pfizer and J